Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

First ADHD treatment recommended through EU centralised authorisation procedure

Guanfacine (Intuniv) should be an option for treating attention deficit-hyperactivity disorder in children and adolescents aged 6 to 17 years, the European Medicines Agency has recommended. In the image, a young girl shouting

Source: Shutterstock.com

Children with ADHD are set to have a new treatment option after the European Medicines Agency recommended the approval of guanfacine

Guanfacine (Intuniv) should be an option for treating attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–17 years for whom stimulants, another type of ADHD medicine, are not suitable or tolerated or have shown to be ineffective, the European Medicines Agency (EMA) has said.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission grants a marketing authorisation for guanfacine but stressed that, like other medicines authorised for the treatment of ADHD, it must only be used as part of a comprehensive treatment programme, typically incorporating psychological, educational and social measures. It must also be initiated under the supervision of an appropriate specialist in childhood or adolescent behavioural disorders.

Shire’s Intuniv is the first treatment for ADHD to be recommended through the centralised authorisation procedure in the EU. The CHMP based its recommendation on 13 studies that provided evidence on the safety and efficacy of the drug in children and adolescents, showing improvements for a number of disease parameters associated with symptom reduction.

The standard pharmacological treatment for ADHD is stimulants, which work by increasing brain activity, particularly in areas that control attention and behaviour. Guanfacine is a selective alpha2–adrenergic agonist, and is expected to improve the symptoms of ADHD by initiating a response from neurons in regions of the brain associated with attention, organisation, planning and impulse control.

The most serious potential side effects of guanfacine are bradycardia, hypotension, syncope, somnolence and sedation and an associated risk of falls and accidents. Treatment is also associated with weight gain.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069072

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Guanfacine (Intuniv) should be an option for treating attention deficit-hyperactivity disorder in children and adolescents aged 6 to 17 years, the European Medicines Agency has recommended. In the image, a young girl shouting

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.